Peptide News Digest

Foundayo ACHIEVE-4 Shows 57% Lower Death Risk, FDA Peptide Panel Analysis, Fifty 1 Labs MSK Push, Nature Communications SbmA Structure

Lilly's Foundayo ACHIEVE-4 data eases FDA concerns with 57% lower death risk; FDA peptide panelists expected to support broader access; non-GLP-1 peptide pipeline advances.

10 stories · Covering clinical-trials, regulatory, industry, research

Editor's Note

Today's digest is anchored by Eli Lilly's ACHIEVE-4 Phase 3 data for Foundayo, which showed a striking 57% lower risk of all-cause death versus insulin glargine — a result that appears to directly address the FDA's April 1 post-market safety concerns and supports Lilly's planned Q2 submission for type 2 diabetes. Beyond GLP-1s, the non-GLP-1 peptide pipeline is accelerating: Fifty 1 Labs announced an AI-driven push into musculoskeletal peptide therapeutics; Enhanced formally responded to the FDA's peptide guidance with plans to expand its Category 1 platform; a Nature Communications paper unveiled the structural mechanism of the antimicrobial peptide transporter SbmA; and BASF launched next-generation collagen peptide actives at In-Cosmetics Global 2026 in Paris. On the regulatory front, STAT News and the Washington Post offered complementary takes on the upcoming July PCAC meeting, with STAT predicting panelists will broadly support RFK Jr.'s legalization push.

Clinical Trials

Lilly ACHIEVE-4: Foundayo Shows 57% Lower All-Cause Death Risk vs Insulin Glargine in Phase 3

Eli Lilly announced positive topline results from ACHIEVE-4, the longest Phase 3 study of Foundayo (orforglipron) to date in 2,700+ adults with type 2 diabetes across 15 countries. The pre-planned analysis showed a 57% lower risk of all-cause death (HR 0.43, p=0.002), while meeting non-inferiority for the prespecified cardiovascular endpoint (HR 0.84). Lilly plans to submit Foundayo for type 2 diabetes to the FDA by end of Q2.

#foundayo #orforglipron #eli-lilly #achieve-4 #type-2-diabetes #cardiovascular
Regulatory

Foundayo Phase 3 Data Seen as Easing FDA's April Safety Concerns

BioSpace analysis frames the ACHIEVE-4 results as a direct answer to the FDA's April 1 letter requesting post-market liver injury and cardiovascular data. The 'outstanding' type 2 diabetes data, combined with cardiovascular safety and all-cause death reductions, strengthens Lilly's position ahead of its Q2 FDA submission and could reduce regulatory friction for the oral GLP-1 franchise.

#foundayo #orforglipron #fda #eli-lilly #drug-safety
Industry

Motley Fool: Retatrutide Could Cement Eli Lilly's Weight Loss Market Leadership

Motley Fool analysis argues that retatrutide — Lilly's triple GLP-1/GIP/glucagon agonist showing up to 28.7% weight loss in Phase 3 TRIUMPH-4 — is the one thing that could firmly cement Lilly's dominance in the obesity drug market. With seven additional Phase 3 readouts expected in 2026 and a projected 2028 launch, retatrutide positions Lilly to extend its lead over Novo Nordisk.

#retatrutide #eli-lilly #obesity #triple-agonist #market-leadership
Regulatory

STAT News: FDA Peptide Advisory Panelists Expected to Support RFK Jr.'s Legalization Push

STAT News analysis of the composition of the July 23-24 Pharmacy Compounding Advisory Committee suggests panelists are likely to vote in favor of broader peptide access. The panel will review BPC-157 (ulcerative colitis), KPV (wound healing), TB-500, MOTS-c, emideltide, semax, and epitalon — largely aligning with RFK Jr.'s February 2026 pledge to move 14 restricted peptides back to Category 1.

#fda #pcac #bpc-157 #kpv #tb-500 #rfk-jr
Industry

Fifty 1 Labs Accelerates AI-Peptide Biotech Push Into Musculoskeletal Health

Fifty 1 Labs (OTC:FITY) announced the expansion of its peptide discovery and clinical research strategy targeting musculoskeletal health, recovery, and performance. The company is building a proprietary peptide discovery engine focused on MSK biology, combining AI-enabled design with staged clinical development for muscle, tendon, ligament, and bone conditions — an area largely overlooked by the GLP-1 dominated peptide pipeline.

#fifty-1-labs #musculoskeletal #ai #peptide-discovery #tissue-repair
Industry

Enhanced Reacts to FDA Peptide Guidance, Plans Platform Expansion for Category 1 Peptides

Enhanced, an elite sports performance and direct-to-consumer peptide company, formally welcomed the FDA's Pharmacy Compounding Advisory Committee meeting schedule. CEO Maximilian Martin stated the reclassification will move peptides 'out of the grey market' and enable licensed compounding access. Enhanced plans to expand its Live Enhanced platform to offer additional peptides once they are formally moved to Category 1.

#enhanced #fda #category-1 #peptide-regulation #compounding
Research

Nature Communications: Antimicrobial Peptide Transporter SbmA Structure Reveals ABC-Like Mechanism

A Nature Communications paper published April 15 reveals shared structural mechanisms between SbmA — an E. coli membrane transporter that imports antimicrobial peptides — and ABC transporters. Using cryo-electron microscopy, EPR spectroscopy, and molecular dynamics simulations, researchers demonstrated SbmA undergoes ABC-transporter-like conformational changes, informing strategies to design antibiotic-resistant-bacteria-penetrating peptide drugs.

#antimicrobial-peptide #sbma #nature-communications #structural-biology #antibiotic-resistance
Industry

In-Cosmetics Global 2026 Opens in Paris, Showcasing BASF's Precision Peptide Collagen Renewal

The three-day In-Cosmetics Global 2026 event opened at Paris Expo Porte de Versailles on April 15, with peptide actives a defining theme. BASF launched NeoHelix Regenerate (41% reduction in damaged collagen at 56 days) and SkinNexus Collag3n (recombinant Collagen III fragment). Gelita showcased its bioactive collagen peptide Verisol for skin elasticity, hydration, and wrinkle reduction.

#in-cosmetics-global #basf #gelita #collagen-peptide #cosmetic-peptides
Clinical Trials

MeiraGTx AAV-hAQP1 Gene Therapy Shows Durable 3-Year Phase 1 Benefit for Radiation-Induced Xerostomia

MeiraGTx announced positive 3-year Phase 1 AQUAx data for AAV-hAQP1, a gene therapy delivering the aquaporin-1 water channel protein via Stensen's duct to the parotid glands of head-and-neck cancer survivors with grade 2/3 radiation-induced dry mouth. Clinically meaningful XQ symptom improvements and unstimulated salivary flow increases were maintained through 3 years. BLA submission planned H1 2027.

#meiragtx #aqp1 #xerostomia #gene-therapy #aav #radiation
Regulatory

Washington Post: FDA Weighs Lifting Peptide Restrictions Amid Wellness Craze

The Washington Post framed the FDA's upcoming July peptide panel through the lens of the exploding wellness craze, noting peptides are pitched as quick fixes for muscle building, injury healing, and anti-aging with minimal supporting research. When the FDA added 19 peptides to its restricted list in 2023, it cited safety risks including cancer and liver, kidney, and heart problems — concerns that have not been resolved.

#fda #peptides #wellness #safety #compounding